Valuation: Grifols SA

Market Cap 5.49B 6.29B 5.08B 4.66B 8.82B 606B 8.98B 60.59B 23.8B 296B 23.6B 23.09B 1,021B P/E 2026 *
12x
P/E 2027 * 8.97x
Enterprise Value 13.88B 15.88B 12.84B 11.78B 22.3B 1,531B 22.69B 153B 60.15B 747B 59.65B 58.34B 2,580B EV / Sales 2026 *
1.81x
EV / Sales 2027 * 1.67x
Free-Float
79.65%
Yield 2026 *
2.84%
Yield 2027 * 3.22%
Manager TitleAgeSince
Chief Executive Officer 57 01/04/2024
Director of Finance/CFO 49 16/09/2024
Compliance Officer 54 01/01/2014
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.18%+1.65%+23.91%-5.51% 67.6B
+0.85%-4.92%+40.11%+199.67% 51.32B
+0.94%+39.60%+39.60%+39.60% 42.97B
+1.71%+0.86%-50.10%-52.11% 40.81B
+5.92%+5.03%+62.63%-25.10% 29.12B
-7.51%-17.52%+96.97%-47.96% 27.09B
+1.36%-1.58%+68.50%+88.88% 22.99B
+0.53%+5.57%+6.29%+200.63% 21.55B
+2.15%-2.72%+64.59%+129.01% 16.38B
Average +0.90%-1.19%+39.17%+58.57% 35.54B
Weighted average by Cap. +1.08%-1.19%+32.99%+49.71%

Financials

2026 *2027 *
Net sales 7.67B 8.78B 7.1B 6.51B 12.32B 846B 12.54B 84.63B 33.24B 413B 32.97B 32.24B 1,426B 8.15B 9.32B 7.53B 6.91B 13.08B 898B 13.31B 89.84B 35.29B 439B 35B 34.23B 1,514B
Net income 511M 585M 473M 434M 821M 56.35B 835M 5.64B 2.21B 27.52B 2.2B 2.15B 94.99B 692M 791M 640M 587M 1.11B 76.26B 1.13B 7.63B 3B 37.24B 2.97B 2.91B 129B
Net Debt 8.39B 9.6B 7.76B 7.12B 13.47B 925B 13.71B 92.53B 36.35B 452B 36.04B 35.25B 1,559B 8.08B 9.24B 7.47B 6.86B 12.97B 891B 13.2B 89.1B 35B 435B 34.71B 33.94B 1,501B
Logo Grifols SA
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-